A65

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Retrieved on: 
Friday, January 5, 2024
Mucorales, Conference, Aspergillosis, Survival, Task, Infection, Biotechnology, NIAID, A65, Lower respiratory tract infection, Antimalarial medication, Trial of the century, Bangladesh Technical Education Board, AAAM, NIH, Vaccine

SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis

Key Points: 
  • SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis
    In this preclinical study, SCY-247 demonstrated in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice.
  • Notably, the combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy.
  • “The results from this preclinical study are very encouraging and illustrate the significant potential for this novel fungerp candidate SCY-247,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS.
  • “Groundbreaking treatment options are urgently needed to address the significant limitations in effective therapies for devastating and very often lethal fungal diseases such as mucormycosis.

SiMa.ai Releases Production Boards Designed to Meet the Challenges of Integrating ML Into Next Generation Embedded Edge Applications

Retrieved on: 
Tuesday, January 31, 2023
Software, Hardware, Electronic Design Automation, Artificial Intelligence, Data Management, Technology, Apps, Applications, Semiconductor, PCI Express, Machine, A65, ML, CVP, Acceleration, Algorithm, Workload, MLA, Temperature, Architecture, K, Computer vision, Silicon, Medical device

SiMa.ai , the machine learning company enabling effortless ML deployment and scaling at the embedded edge, today announced availability of two new PCIe-based production boards that scales embedded edge ML deployments for key customers.

Key Points: 
  • SiMa.ai , the machine learning company enabling effortless ML deployment and scaling at the embedded edge, today announced availability of two new PCIe-based production boards that scales embedded edge ML deployments for key customers.
  • The availability of these two new commercially deployable board-level products demonstrates the commitment of SiMa.ai's mission to simplify ML scalability at the embedded edge.
  • The company also announced its Palette™ software that provides a pushbutton experience for developing complete end-to-end ML applications targeting the heterogeneous SiMa.ai Machine Learning SoC (MLSoC™) platform.
  • The efficiency of the MLSoC architecture provides the ability to meet the power constraints of the smallest embedded edge form factors.